GlassScriptPhysician profile
David Lawrence Patick
NPI 1972546273
$18,032.32
in general payments reported to CMS, 2019-2025
60 companies · $2,528 in 2025
The $2,528 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,570 · 2020: $2,154 · 2021: $2,167 · 2022: $2,468 · 2023: $2,305 · 2024: $2,841 · 2025: $2,528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,674.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,674.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,006.58 | 2019-2025 | Farxiga, Breztri, Tezspire |
| Novo Nordisk INC | $1,808.06 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,607.16 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $1,335.54 | 2019-2025 | |
| Abbvie INC. | $1,239.65 | 2021-2025 | |
| Amgen INC. | $1,074.77 | 2019-2025 | Evenity, Otezla, Repatha |
| Lilly USA, LLC | $1,026.49 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $756.30 | 2019-2025 | Jardiance, Ofev |
| Pfizer INC. | $688.55 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $589.73 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $584.03 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $510.82 | 2019-2021 | |
| Amarin Pharma, INC. | $431.11 | 2019-2021 | |
| Paratek Pharmaceuticals, INC. | $408.23 | 2024-2025 | Nuzyra, Xhance |
| Teva Pharmaceuticals USA, INC. | $279.75 | 2020-2022 |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $274.32 | 2021-2025 | |
| Vifor Pharma, INC. | $267.33 | 2020-2023 | Korsuva, Veltassa |
| Esperion Therapeutics, INC. | $244.31 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $242.75 | 2022-2024 | Jynarque, Rexulti |
| Shield Therapeutics INC | $220.69 | 2023-2024 | Accrufer |
| Abbott Laboratories | $203.59 | 2019-2024 | Proclaim, Freestyle Libre 3 |
| Avanir Pharmaceuticals, INC. | $189.70 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $169.30 | 2019-2025 | Glassia |
| Argenx US, INC. | $159.74 | 2022-2024 | Vyvgart Hytrulo, Vyvgart |
| Kowa Pharmaceuticals America, INC. | $144.94 | 2019-2023 | Seglentis, Livalo |
| Sanofi-Aventis U.S. LLC | $143.68 | 2019-2020 | |
| Allergan, INC. | $134.08 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $125.65 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $124.35 | 2020-2021 | |
| Dexcom, INC. | $111.76 | 2023-2025 | Dexcom G6 Transmitter |
| Alexion Pharmaceuticals, INC. | $91.27 | 2022-2024 | Ultomiris, Soliris |
| Mylan Specialty L.P. | $70.18 | 2022-2023 | Yupelri |
| Sunovion Pharmaceuticals INC. | $66.86 | 2021 | |
| Lundbeck LLC | $59.64 | 2020-2024 | Rexulti |
| Intercept Pharmaceuticals, INC. | $46.27 | 2020-2021 | |
| Xeris Pharmaceuticals, INC. | $44.41 | 2022-2024 | Gvoke Hypopen |
| Cvrx, INC. | $36.61 | 2024 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $34.47 | 2021-2025 | Capvaxive, Gardasil 9 |
| Endo Pharmaceuticals INC. | $33.68 | 2020 | |
| Corium, LLC | $30.01 | 2023 | Azstarys |
| Shire North American Group INC | $29.34 | 2019 | |
| Ironwood Pharmaceuticals, INC | $29.00 | 2019-2021 | |
| Aurinia Pharma U.S., INC. | $27.95 | 2021 | |
| Genentech USA, INC. | $26.59 | 2020 | |
| Corcept Therapeutics | $26.39 | 2021 | |
| Phathom Pharmaceuticals, INC. | $23.68 | 2024-2025 | Voquezna |
| Philips North America LLC | $23.38 | 2024 | (5044) Mcot |
| Kyowa Kirin, INC. | $21.48 | 2025 | |
| Insulet Corporation | $21.46 | 2024 | Omnipod |
| Baxter Healthcare | $20.75 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Smith+Nephew, INC. | $19.88 | 2022 | |
| Scpharmaceuticals INC. | $19.26 | 2025 | |
| Ferring Pharmaceuticals INC. | $18.15 | 2023 | Rebyota |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.69 | 2022 | |
| Exact Sciences Corporation | $17.58 | 2023 | Cologuard Collection Kit |
| Melinta Therapeutics, LLC | $16.04 | 2019 | |
| Janssen Biotech, INC. | $16.01 | 2020 | |
| Boston Scientific Corporation | $14.40 | 2024 | Watchman Flx |
| Eisai INC. | $13.74 | 2021 | |
| Neurocrine Biosciences, INC. | $13.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Patick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.